GT Biopharma to Present at Raymond James Human Health Innovation Conference

Rhea-AI Summary

GT Biopharma, a clinical stage immuno-oncology company, will provide a corporate update at the Raymond James Human Health Innovation Conference on June 22, 2021, at 11:20 AM ET. The presentation will showcase developments from their proprietary TriKE™ NK cell engager platform. A live webcast can be accessed via the company's website, with an archive available for 30 days post-event. GT Biopharma holds an exclusive agreement with the University of Minnesota for further therapy development.

BEVERLY HILLS, Calif., June 16, 2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, today announced that it will provide a corporate update at the upcoming Raymond James Human Health Innovation Conference on Tuesday, June 22, 2021 at 11:20 AM ET.

A live webcast of the event will be available by visiting "Presentations" page in the Investors section of GT Biopharma's website at www.gtbiopharma.com/news-media/presentations. A replay of the webcast will be archived for 30 days following the presentation.

About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE™ NK cell engager platform.  Our TriKE™ platform is designed to harness and enhance the cancer killing abilities of a patient's immune system's natural killer cells (NK cells).  GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE™ technology. For more information, please visit gtbiopharma.com.

Investor Contact:	Investor and Media Relations Contact:
Brendan Payne	David Castaneda
Client Lead	David@gtbiopharma.com
Stern Investor Relations, Inc.	414-351-9758
brendan.payne@sternir.com
212-362-1200

 

View original content:http://www.prnewswire.com/news-releases/gt-biopharma-to-present-at-raymond-james-human-health-innovation-conference-301313508.html

SOURCE GT Biopharma, Inc.

FAQ

What is GT Biopharma presenting at the Raymond James Human Health Innovation Conference?

GT Biopharma will provide a corporate update regarding its immuno-oncology developments based on its TriKE™ platform.

When will the GT Biopharma presentation take place?

The presentation is scheduled for June 22, 2021, at 11:20 AM ET.

How can I watch the GT Biopharma conference presentation?

You can watch the live webcast on GT Biopharma's website.

Will there be a replay of the GT Biopharma presentation?

Yes, a replay of the presentation will be archived for 30 days after the live event.

What is the focus of GT Biopharma's research?

GT Biopharma focuses on developing therapies using its proprietary TriKE™ NK cell engager platform to enhance cancer treatment.